At least 13 biotechs have proposed IPOs, including two being spun out of other biotechs. Harvard Apparatus Regenerative Technology Inc. is being spun out of Harvard Biosciences Inc. (NASDAQ:HBIO), and Audeo Oncology Inc is being spun out of Alchemia Ltd. (ASX:ACL). Unless noted, the companies are seeking to list on NASDAQ. (A) If proposed shares and price range are available, the mid-point was used to calculate the amount to be raised; (B) Status at time of filing; (C) Re-filed IPO; Source: BCIQ: BioCentury Online Intelligence

Company

Date filed

To be raised (A)

Status (B)

Harvard Apparatus Regenerative Technology Inc.

12/11/12

Up to $20M

Mkt (device)

Enanta Pharmaceuticals Inc.

11/6/12

Up to $69M

Ph III

KaloBios Pharmaceuticals Inc.

10/5/12

Up to $60M

Ph II

Paratek Pharmaceuticals Inc.

9/27/12

Up to $92M

Ph III start 1Q13

AutoGenomics Inc. (C)

9/26/12

Up to $65M

Mkt (diagnostic)

Audeo Oncology Inc.

7/6/12

$48.8M

Ph III

GlobeImmune Inc.

7/2/12

$60M

Ph IIb

OncoMed Pharmaceuticals Inc.

5/11/12

Up to $115M

Ph I

Stemline Therapeutics Inc.

4/2/12

$25M

Ph I/II

Newsummit Biopharma Holdings Ltd. (NYSE)

2/24/12

Up to $80M

Mkt (services)

Cancer Genetics Inc.

12/30/11

$35M

Mkt (diagnostic)

Emmaus Life Sciences Inc.

7/11/11

Up to $46M

Mkt (drug)

LipoScience Inc.

6/23/11

$70M

Mkt (diagnostic)